May 22, 2019
Japan Kidney Association
Otsuka Pharmaceutical Co., Ltd.
Otsuka and Japan Kidney Associationto Collaborative on Autosomal Dominant Polycystic Kidney Disease
Otsuka Pharmaceutical Co., Ltd. and the Japan Kidney Association, a non-profit organization, have concluded a comprehensive agreement to collaborate in Japan on raising the level of disease awareness and medical care for autosomal dominant polycystic kidney disease (ADPKD), a rare and incurable disease of the kidney.
The Japan Kidney Association and Otsuka will utilize their respective strengths and accumulated experience in the field of nephrology in order to advance the contributions possible to patients with ADPKD and their families.
Chronic kidney diseases impair the healthy lifespans of people afflicted with them. Among them, ADPKD, which is a hereditary and intractable disease, calls for earlier diagnosis, prevention of deterioration of the disease, and broader awareness of it among society and the health professions.
More specific information about the collaboration will be communicated at a later date.
Information in this news release was current as of the original release date.
Latest Pharmaceutical Business related News Releases
- 18 APR 2019
- Erdafitinib Receives Regulatory Approval in U.S.